The Efficacy of Single Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: A Real-Life Results
| Autor: | Simsek, Mert, Citirik, Mehmet, Ozates, Serdar, Tekin, Kemal, Ozkoyuncu, Dilara |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Anti vegf
medicine.medical_specialty recurrence genetic structures business.industry efficacy Diabetic macular edema eye diseases Anesthesiology and Pain Medicine lcsh:Ophthalmology intravitreal dexamethasone implant Refractory lcsh:RE1-994 Ozurdex Ophthalmology medicine Original Article Implant business Dexamethasone medicine.drug |
| Zdroj: | Beyoglu Eye Journal Beyoglu Eye Journal, Vol 5, Iss 1, Pp 43-48 (2020) |
| ISSN: | 2459-1777 |
| DOI: | 10.14744/bej.2020.06977 |
| Popis: | INTRODUCTION[|]To investigate the efficacy, safety, and side effect profiles of a single-dose intravitreal dexamethasone implant (IDI, Ozurdex) in patients with diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) therapy.[¤]METHODS[|]This study included 101 eyes of 78 diabetic patients with DME that remained persistent despite administering at least six doses of anti-VEGF therapy. The patients were evaluated at baseline and were followed up monthly until the sixth month after the IDI injection. The primary outcomes were central foveal thickness (CFT) and best-corrected visual acuity (BCVA).[¤]RESULTS[|]The mean number of anti-VEGF injection administered to patients was 6.50+-0.33. One month after the last injection, the response to treatment was evaluated. IDI injection was performed approximately 1.14+-0.08 months after the last anti-VEGF injection. After the IDI injection, BCVA value increased (p50% patients in the sixth month after the first injection.[¤] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|